Related by context. All words. (Click for frequent words.) 72 medulloblastoma 70 metastatic melanoma 70 glioblastoma multiforme GBM 69 gliomas 69 Glioblastoma 68 multiple myeloma 68 metastatic cancer 68 tumors 68 lymphomas 67 acute myeloid leukemia 67 chronic lymphocytic leukemia CLL 66 CLL 66 glioma 66 gastrointestinal stromal tumors 66 solid tumors 66 sarcomas 65 renal cell carcinoma 65 melanoma 65 glioblastomas 65 brain tumors 64 NSCLC 64 brain tumor glioblastoma multiforme 64 malignancies 64 glioblastoma multiforme 64 follicular lymphoma 64 synovial sarcoma 64 lymphoma 64 Burkitt lymphoma 64 non Hodgkin lymphoma 64 acute myelogenous leukemia AML 63 pancreatic adenocarcinoma 63 leukemia AML 63 anaplastic 63 neuroblastoma 63 acute lymphoblastic leukemia 63 neuroendocrine tumors 63 leukemias 63 leukemia CLL 63 carcinoma 63 rhabdomyosarcoma 63 acute myeloid leukemia AML 62 malignant gliomas 62 leukemia ALL 62 cancers 62 Glioblastoma multiforme GBM 62 tumor 62 medulloblastomas 62 Gleevec resistant 62 ovarian tumors 62 GIST 62 HER2 positive breast cancer 62 Glioblastoma multiforme 62 lymphoblastic leukemia 62 pancreatic cancers 62 heavily pretreated 62 gastrointestinal stromal tumor GIST 62 ependymoma 61 Glioblastoma Multiforme 61 metastatic disease 61 leukemia 61 metastatic colon cancer 61 carcinoid tumors 61 gastrointestinal stromal tumor 61 medullary thyroid cancer 61 malignancy 61 myelofibrosis 61 metastatic colorectal cancer 61 breast tumors 61 sarcoma 61 ovarian cancer 60 Follicular lymphoma 60 differentiated thyroid 60 chronic myelogenous leukemia CML 60 lung tumors 60 recurrent glioblastoma multiforme GBM 60 metastatic renal cell carcinoma 60 astrocytoma 60 brain metastases 60 recurrent glioblastoma 60 chronic myeloid leukemia CML 60 cell acute lymphoblastic 60 hepatocellular carcinoma HCC 60 metastatic breast cancer 60 cilengitide 60 dasatinib 60 recurrent glioblastoma multiforme 60 malignant melanoma 60 DLBCL 60 advanced NSCLC 60 breast carcinomas 60 imatinib Gleevec 60 indolent NHL 60 prostate cancers 60 carcinoid 60 Acute Lymphoblastic Leukemia 60 Waldenstrom macroglobulinemia 60 carcinoid cancer 60 metastatic 59 hepatocellular carcinoma 59 Cholangiocarcinoma 59 Acute Myelogenous Leukemia AML 59 castration resistant prostate cancer 59 Ewing sarcoma 59 Glioblastoma Multiforme GBM 59 hematologic malignancies 59 EGFRvIII 59 metastatic malignant melanoma 59 tyrosine kinase inhibitors 59 acute myelogenous leukemia 59 bone metastasis 59 PARP inhibitors 59 pancreatic carcinoma 59 GISTs 59 acute lymphoblastic 59 metastatic lung cancer 59 myeloma cells 59 basal cell carcinoma BCC 59 adenocarcinoma 59 Glioblastomas 59 leukaemias 59 FLT3 59 grade gliomas 59 metastatic prostate cancer 59 osteosarcoma 59 HER2 positive metastatic breast 59 hematological cancers 59 HER2 positive 59 prostate tumors 59 pancreatic tumors 59 prostate tumor 58 cancer 58 nonsmall cell lung cancer 58 metastases 58 Acute lymphoblastic leukemia 58 PCNSL 58 GBM tumors 58 glioblastoma tumors 58 PLX# 58 neuroendocrine cancers 58 acute lymphocytic leukemia 58 metastasis 58 EGFR inhibitors 58 malignant tumors 58 pancreatic cancer 58 leiomyosarcoma 58 bortezomib 58 KRAS wild 58 alveolar rhabdomyosarcoma 58 carcinomas 58 acute promyelocytic leukemia 58 myeloproliferative disorders 58 acute leukemias 58 lymphocytic leukemia 58 lupus nephritis 58 colorectal cancer 58 hematological malignancies 58 metastatic kidney 58 imatinib 58 squamous cell carcinoma 58 superficial bladder cancer 58 Acute Myelogenous Leukemia 58 nasopharyngeal carcinoma 58 sorafenib 58 glioblastoma GBM 58 WT1 58 chronic myeloid leukemia 58 Non Hodgkin lymphoma 57 BCR ABL 57 liver metastases 57 chronic lymphocytic leukemia 57 chemotherapeutic agent 57 gastric cancer 57 HER2 positive cancers 57 DIPG 57 liver cancer 57 recurrent NSCLC 57 tumor cells 57 oligodendroglioma 57 thymoma 57 chronic myelogenous leukemia 57 tumors GIST 57 Mantle Cell Lymphoma 57 MALT lymphoma 57 relapsing remitting multiple sclerosis 57 Metastatic melanoma 57 Acute myeloid leukemia 57 EGFR mutation 57 malignant glioma 57 cell lymphomas 57 angiogenesis inhibitor 57 JMML 57 anaplastic astrocytoma 57 seminoma 57 BRAF mutation 57 myeloid leukemia 57 Glioma 57 PKCi 57 metastatic tumors 57 metastatic renal cell 57 acute leukemia 57 diagnosed glioblastoma multiforme 57 CLL cells 57 lymphoma CTCL 57 Hepatocellular Carcinoma HCC 57 mRCC 57 relapsed refractory 57 metastatic lesions 57 anti angiogenic therapy 57 lymphoblastic lymphoma 57 chemotherapy regimens 57 EGFR mutations 57 prostate adenocarcinoma 57 Hodgkin Lymphoma 57 epithelial tumors 57 thymic carcinoma 57 temozolomide 57 Non Hodgkins lymphoma 57 malignant pleural mesothelioma 57 essential thrombocythemia 57 panobinostat 57 diffuse intrinsic pontine glioma 57 melanoma tumors 57 Hodgkin lymphoma 57 breast cancers 57 Rhabdomyosarcoma 57 squamous cell cancer 57 IV melanoma 57 Wilms tumor 57 Chronic lymphocytic leukemia 56 hematological malignancy 56 AP# [003] 56 Acute Lymphocytic Leukemia 56 T#I mutation 56 multiple myeloma MM 56 metastatic cancers 56 MMP inhibitors 56 hypophosphatasia 56 osteosarcomas 56 xenograft models 56 myelodysplastic syndrome MDS 56 GIST tumors 56 acute promyelocytic leukemia APL 56 pancreatic NET 56 cisplatin resistant 56 IV metastatic melanoma 56 recurrent GBM 56 inherited neurodegenerative disorder 56 pancreatic tumor 56 B CLL 56 Hodgkin lymphoma NHL 56 squamous cell 56 prostate cancer PCa 56 angiosarcoma 56 Acute Leukemia 56 sunitinib 56 ovarian cancers 56 cell lung cancer 56 pertuzumab 56 ipilimumab 56 Osteosarcoma 56 HCV infection 56 Wegener granulomatosis 56 imatinib resistant 56 cell carcinoma 56 papillary thyroid cancer 56 endometrial cancers 56 HDAC inhibitors 56 acute myelogenous 56 indolent lymphoma 56 pheochromocytoma 56 Acute Lymphoblastic Leukaemia 56 sorafenib Nexavar ® 56 gastrointestinal stromal tumors GIST 56 nonmelanoma skin cancers 56 SCCHN 56 epithelial cancers 56 enzastaurin 56 T#I [002] 56 castrate resistant 56 breast carcinoma 56 uveal melanoma 56 histologies 56 Lymphoma 56 malignant transformation 56 Kaposi sarcoma 56 renal cell carcinomas 56 embryonal rhabdomyosarcoma 56 ADPKD 55 gastric cancers 55 GvHD 55 paraganglioma 55 lung adenocarcinoma 55 Carcinoma 55 gemcitabine 55 Acute Myeloid Leukemia 55 AAV2 55 advanced carcinoid 55 astrocytomas 55 invasive ductal carcinoma 55 prostate cancer CRPC 55 Chronic lymphocytic leukemia CLL 55 receptor tyrosine kinase inhibitor 55 recurrent ovarian cancer 55 colon cancer 55 prostate carcinoma 55 lupus 55 olaparib 55 pleural mesothelioma 55 oncogenes 55 rituximab 55 GBMs 55 neuroblastomas 55 EGFR 55 cytogenetic responses 55 cutaneous melanoma 55 papillary renal cell carcinoma 55 BRAF gene 55 EGFr 55 Myelodysplastic Syndrome 55 squamous 55 hepatocellular cancer 55 gefitinib Iressa 55 K ras mutations 55 myeloproliferative disorder 55 EGF receptor 55 hematologic disorders 55 Bezielle 55 Non Hodgkin Lymphoma 55 Dr. Victor Velculescu 55 myelofibrosis polycythemia vera 55 targeting CD# 55 Gliomas 55 hedgehog pathway 55 PCa 55 pancreatic neuroendocrine tumors 55 GBM 55 NF2 55 CD# mAb 55 angiogenesis inhibition 55 scleroderma 55 oligodendrogliomas 55 bladder cancers 55 myelogenous leukemia 55 Tamibarotene 55 imetelstat 55 IDH2 55 mCRC 55 colorectal liver metastases 55 malignant lymphoma 55 anti leukemic 55 myeloproliferative diseases 55 chemotherapeutic agents 55 trans retinoic acid 55 Pancreatic cancer 55 sarcomatoid 55 acute myeloid 55 Acute Myeloid Leukemia AML 55 BRAF V#E mutation 55 lobular carcinoma 55 NF1 55 renal carcinoma 55 ovarian carcinoma 55 Anaplastic 55 ErbB2 positive 55 tyrosine kinase inhibitors TKIs 55 anti TNF 55 K ras 55 HGS ETR1 55 Chronic Lymphocytic Leukemia CLL 55 hormone refractory prostate cancer 55 gastrointestinal cancers 55 IMGN# 55 relapsed leukemia 55 flavopiridol 55 colorectal tumors 55 heavily pretreated patients 55 anticancer therapies 55 esophageal adenocarcinoma 55 AMN# [001] 55 retinoblastoma 55 ependymomas 55 relapsed multiple myeloma 55 metastatic bladder 55 colon carcinoma 55 Melanoma 55 leukemic cells 55 malignant brain 54 PTLD 54 squamous cell carcinoma SCC 54 erlotinib 54 gefitinib 54 JAK2 54 Hedgehog pathway 54 polycythemia vera 54 relapsing remitting 54 HRPC 54 chronic granulomatous disease 54 grade glioma 54 lung metastases 54 prostate cancer 54 relapsing remitting MS 54 tumor regression 54 docetaxel chemotherapy 54 haematological cancers 54 depsipeptide 54 cell lymphoma CTCL 54 standard chemotherapy regimens 54 neuroendocrine carcinoma 54 neuroblastoma tumor 54 dasatinib Sprycel 54 Imatinib 54 subependymal giant cell 54 pediatric acute lymphoblastic 54 bendamustine 54 lung cancers 54 leukemia CML 54 cell lymphoma 54 premalignant 54 monoclonal antibody therapies 54 Leukemias 54 anticancer agents 54 microRNA miR 54 GVHD 54 Burkitt Lymphoma 54 proteasome inhibitors 54 primitive neuroectodermal tumor 54 anaplastic thyroid cancer 54 lung metastasis 54 pilocytic astrocytoma 54 anaplastic astrocytoma AA 54 brain tumor 54 frontotemporal dementia 54 Annamycin 54 CLL SLL 54 vemurafenib 54 serous ovarian cancer 54 relapsed ovarian cancer 54 pomalidomide 54 non Hodgkin lymphomas 54 pazopanib 54 bleomycin 54 familial ALS 54 idiopathic pulmonary fibrosis IPF 54 multiforme 54 cervical carcinoma 54 Philadelphia Chromosome Positive 54 prostate cancer CaP 54 adenocarcinomas 54 KRAS mutation 54 Zolinza 54 cell malignancies 54 basal cell carcinoma 54 metastatic colorectal 54 AEG# 54 operable breast cancer 54 mTOR inhibitors 54 dyskeratosis congenita 54 Cutaneous T 54 imatinib therapy 54 HER2 + 54 Myelofibrosis 54 antitumor 54 Hodgkin lymphoma HL 54 Chronic myeloid leukemia CML 54 Gleevec 54 beta thalassemia 54 tumor shrinkage 54 myeloma 54 HNSCC 54 taxane therapy 54 adrenocortical carcinoma 54 cancerous tumors 54 chemoresistance 54 proteasome inhibitor 54 DFMO 54 invasive breast cancer 54 IMC A# 54 neuroblastoma cells 54 malignant pancreatic 54 soft tissue sarcomas 54 disease progression 54 topotecan 54 PARP inhibition 54 androgen independent 54 Myelodysplastic Syndrome MDS 54 myeloablative 54 KRAS gene 54 Cell Lymphoma 54 diabetic nephropathy 54 T#I mutant 54 malignant pheochromocytoma 54 poly ADP ribose polymerase 54 imatinib Gleevec ® 54 CYT# potent vascular disrupting 54 PARP inhibitor 54 systemic lupus erythematosus 54 myelodysplastic syndrome 54 myeloproliferative neoplasms 54 VEGF inhibitors 54 Kit CD# positive 54 BRAF V# mutation 54 glioma cells 54 alvespimycin 54 biliary tract cancer 54 metastatic RCC 54 MGd 54 oncoproteins 54 unresectable stage 54 Omacetaxine 54 rindopepimut 54 sporadic ALS 54 Metastatic 53 IDH1 53 FSGS 53 non squamous 53 chemotherapies 53 NSCLC tumors 53 resistant ovarian cancer 53 complete remissions 53 anticancer therapy 53 Tarvacin 53 JAK3 53 chronic myeloid 53 AA amyloidosis 53 leukemia APL 53 axitinib 53 ccRCC 53 Crizotinib 53 Epstein Barr virus EBV 53 malignant growths 53 Velcade bortezomib 53 amrubicin 53 squamous cell lung cancer 53 relapsed AML 53 tumor recurrence 53 pulmonary metastases 53 hTERT 53 JAK mutations 53 invasive ductal 53 cancer mCRC 53 lung adenocarcinomas 53 HER2 53 Duchenne muscular dystrophy DMD 53 pancreatic colon 53 lymphocytosis 53 BRAF inhibitor 53 leukemic stem cells 53 cutaneous T cell 53 T DM1 53 gamma secretase inhibitor 53 Cotara 53 vandetanib 53 systemic lupus 53 anticancer drugs 53 hypereosinophilic syndrome 53 galiximab 53 Hsp# inhibition 53 chemotherapy 53 colorectal cancers 53 systemic lupus erythematosus SLE 53 CBLC# 53 Bortezomib 53 PNP inhibitor 53 CD# [002] 53 neuroblastoma tumors 53 BRCA deficient 53 endostatin 53 huN# DM1 53 molecularly targeted 53 Non Hodgkins Lymphoma 53 cutaneous T 53 relapsed refractory multiple myeloma 53 mutated KRAS gene 53 Neuroblastoma 53 nasopharyngeal cancer 53 dermatofibrosarcoma protuberans 53 GRN# 53 cholangiocarcinoma 53 cisplatin 53 interferon alpha 53 lung fibrosis 53 abiraterone 53 epithelial ovarian cancer 53 MYCN amplification 53 colorectal carcinoma 53 cisplatin chemotherapy 53 xenograft tumors 53 AML acute myeloid 53 myeloid cells 53 aHUS 53 PSADT 53 commercialize deforolimus 53 prostate cancer mCRPC 53 HER2 positive tumors 53 Multiple myeloma 53 adjuvant therapy 53 papillary carcinoma 53 Multiple Myeloma 53 ovarian tumor 53 BRAF V#E 53 basal cell carcinomas 53 renal tumors 53 activating mutations 53 malignant fibrous histiocytoma 53 mycosis fungoides 53 urothelial cancer 53 TTF Therapy 53 nodular melanoma 53 tyrosine kinase inhibitor 53 orthotopic model 53 Rituxan rituximab 53 Testicular cancer 53 papillary 53 eosinophilic esophagitis 53 refractory ovarian cancer 53 IGF IR 53 myeloid 53 cranial radiation 53 Alemtuzumab 53 TTR amyloidosis 53 antitumor activity 53 erlotinib Tarceva ® 53 Enzastaurin 53 refractory chronic myeloid 53 breast cancer subtypes 53 sorafenib Nexavar 53 refractory indolent non 53 myotonic dystrophy 53 Doxil ® 53 neoadjuvant therapy 53 hepatitis C genotype 53 Herceptin trastuzumab 53 refractory prostate cancer 53 gastrointestinal GI cancers 53 Atiprimod 53 SOD1 53 meningioma 53 bortezomib Velcade 53 cetuximab 53 refractory CML 53 biologic therapies 53 CMV infection 53 prostate cancer AIPC 53 HER2/neu 53 TKIs 53 BAY #-# 53 neurodegenerative disease 53 meningiomas 53 telomerase inhibition 53 Carboplatin 53 HER2 receptor 53 homozygous familial hypercholesterolemia 53 GRP# 53 B7 H3 53 allogeneic transplants 53 bladder tumors 53 FGFR2 53 distant metastasis 53 cediranib 53 breast cancer metastasis 53 locoregional 53 pDCs 53 Synovial sarcoma 53 refractory acute myeloid 53 HCV infected 53 gastric carcinoma 53 XmAb# 53 bone metastases 53 carcinoid tumor 53 acute lymphoid leukemia 53 ENMD # 53 myelodysplastic syndromes 53 JAK1 53 neoplasm 53 Dasatinib 53 EGFR pathway 53 Myelodysplastic syndrome 53 metastatic malignant 53 atypical rhabdoid tumor 53 TTR gene 53 OncoVEX GM CSF 52 YONDELIS 52 Hodgkin Disease 52 subtype 52 follicular non 52 pancreatic islet cell 52 distant metastases 52 colorectal cancer liver metastases 52 diagnose Alzheimer disease 52 hematologic cancers 52 gastric adenocarcinoma 52 Crohn disease 52 mutated BRAF gene 52 immunotherapies 52 non hodgkin lymphoma 52 peritoneal carcinomatosis 52 IRX 2 52 calcitriol 52 IDH1 mutation 52 allogeneic bone marrow 52 Ceflatonin 52 molecular subtypes 52 ovarian lung 52 G CSF 52 EpCAM 52 CD# antigen 52 Symadex 52 Gleevec imatinib 52 hematologic 52 obatoclax 52 immunomodulator 52 tumor suppressor genes 52 curable cancers 52 metastatic gastric 52 BRAF mutations 52 SPINK1 52 follicular lymphomas 52 colon cancers 52 tumor metastases 52 PI3K Akt 52 metastatic melanomas 52 vorinostat 52 Gefitinib 52 ganetespib 52 smoldering myeloma 52 pediatric malignancies 52 factor receptor 52 FTLD 52 Pertuzumab 52 carfilzomib 52 hepatoma 52 basal cell nevus syndrome 52 neurodegenerative disorder 52 squamous cell carcinomas 52 Diffuse Intrinsic Pontine Glioma 52 tumorigenic 52 EGFR tyrosine kinase inhibitors 52 refractory CLL 52 chlorambucil 52 follicular lymphoma FL 52 TACE 52 decitabine 52 Follicular Lymphoma 52 mutational status 52 melanomas 52 pilocytic astrocytomas 52 KRAS mutant 52 CXCR4 52 Pralatrexate 52 PIK3CA 52 proto oncogene 52 refractory multiple myeloma 52 recurrent glioma 52 endocrine tumors 52 IGF 1R 52 thalidomide Thalomid 52 tumoral 52 stem cell transplantation 52 follicular NHL 52 CDK4 52 lymphoid malignancies 52 mutated KRAS 52 medically inoperable 52 OHR/AVR# 52 lysosomal storage diseases 52 Flt3 52 histone deacetylase inhibitors 52 VEGFR2 52 Hurler syndrome 52 figitumumab 52 multi kinase inhibitor 52 chemoradiotherapy 52 Peutz Jeghers syndrome 52 leukemias lymphomas 52 ELACYT 52 demethylating agents 52 demonstrated antitumor activity 52 imatinib resistance 52 lung cancer 52 interferon pathway 52 Hurthle cell 52 inoperable pancreatic cancer 52 factor receptor EGFR 52 juvenile myelomonocytic leukemia 52 castrate resistant prostate cancer 52 cytoreduction 52 micrometastases 52 prostate cancer HRPC 52 transgenic mice 52 dasatinib Sprycel ® 52 alkylating agents 52 erlotinib Tarceva 52 Medulloblastoma 52 glioblastoma tumor 52 Wilms tumors 52 JAK inhibitors 52 Stat5 52 hypomethylating agents 52 xenografts 52 NPM1 52 refractory CTCL 52 familial amyloidotic polyneuropathy FAP 52 LHRH receptor positive 52 relapsing multiple sclerosis 52 tumor subtypes 52 untreated metastatic melanoma 52 Ebola virus infection 52 systemic ALCL 52 Vectibix 52 cytokine refractory 52 OXi# 52 pegylated liposomal doxorubicin 52 INGN 52 malaria parasite Plasmodium falciparum 52 lymphoid cells 52 Medullary thyroid cancer 52 commonly mutated genes 52 forodesine 52 irinotecan chemotherapy 52 chemotherapy regimen 52 IMA# 52 malignant cells 52 papillary RCC 52 durable remissions 52 lymphoproliferative disorders 52 Akt1 52 thyroid carcinoma 52 Merkel cell carcinoma 52 ixabepilone 52 HER2 overexpression 52 Friedreich ataxia 52 malignant prostate 52 Niemann Pick disease 52 fungal meningitis 52 squamous cell cancers 52 glioma rarer 52 refractory AML 52 diagnosed GBM 52 oncogenesis 52 metastatic GIST 52 neutralizing antibody 52 stage IIIB IV 52 MDS AML 52 VZV 52 mTOR inhibitor 52 metastatic uveal melanoma 52 cabazitaxel 52 complete cytogenetic 52 cutaneous squamous cell carcinoma 52 Malignant melanoma 52 hypoxia inducible factor 52 anti angiogenic drugs 52 acromegaly 52 polycythemia vera PV 52 cetuximab Erbitux 52 p# biomarker 52 chemo resistant 52 bevacizumab Avastin ® 52 pemphigus vulgaris 52 TKI therapy 52 MGUS 52 CMV disease 52 relapsed GBM 52 mapatumumab 51 FOLFOX chemotherapy 51 LRRK2 51 chemoresistant 51 Aplidin 51 Malignant Melanoma 51 CYC# 51 vWD 51 GNAQ 51 anaplastic lymphoma kinase 51 XL# [003] 51 Waldenstrom Macroglobulinemia 51 interferons 51 pegfilgrastim 51 myelodysplastic syndromes MDS 51 interferon 51 INCB# [003] 51 N Myc 51 perifosine 51 ER CHOP 51 oncoprotein 51 adenoma 51 Renal cell carcinoma 51 recurrent malignant glioma 51 hematopoietic cell 51 relapsed MM 51 anthrax toxin 51 metastatic hormone refractory 51 Ewing sarcoma rare 51 postoperative pathology 51 phase IIb clinical 51 HbF 51 pan HDAC inhibitor 51 Advexin 51 nilotinib 51 rhabdoid 51 neoadjuvant chemotherapy 51 Malignant glioma 51 hepatoblastoma 51 prognostic indicator 51 Leber congenital amaurosis LCA 51 Smad7 51 pituitary adenomas 51 TREANDA 51 gemcitabine carboplatin 51 homozygous FH 51 Smac mimetic 51 non metastatic osteosarcoma 51 liver metastasis 51 Meningiomas 51 blinatumomab 51 Proxinium TM 51 lymphoid 51 B lymphocyte 51 Idiopathic Pulmonary Fibrosis IPF 51 Pleural mesothelioma 51 Median survival 51 MEK inhibitors 51 HDACi 51 HCV infections 51 fusion protein 51 azacitidine 51 infantile spasms 51 Chronic Myeloid Leukemia CML 51 hepatitis C virus 51 histologic subtype 51 NFkB 51 SATB1 51 PNET 51 HER2 negative 51 severe sepsis 51 elacytarabine 51 overexpress 51 molecular abnormalities 51 ON #.Na 51 bone marrow stem cells 51 ptau 51 chemoradiation 51 castration resistant 51 Barrett esophagus 51 ALCL 51 kinase inhibitor 51 Sym# 51 Torisel 51 metastatic pancreatic cancer 51 B lymphocytes 51 cells hESCs 51 temsirolimus 51 Tumours 51 alkylating agent 51 Aurora kinase 51 cytotoxic chemotherapy 51 KRAS mutations 51 aneuploid cells 51 Metastasis 51 Cytoxan 51 HCV genotypes 51 HBeAg negative 51 systemic scleroderma 51 VEGF receptor 51 CYT# 51 MDV# 51 antiviral therapies 51 liposarcoma 51 ara C 51 nonmetastatic 51 inhibit tumor 51 teratoma 51 chemotherapeutic 51 thyroid cancers 51 Fanconi anemia 51 PDGF receptor 51 HGS# 51 cytogenetic response 51 Azedra 51 Mesenchymal 51 metastatic carcinoma 51 talabostat 51 severe aplastic anemia 51 tumor progression 51 pancreatic ductal adenocarcinoma 51 hematopoietic cells 51 primitive neuroectodermal tumors 51 mCRC patients 51 milatuzumab 51 bladder carcinoma 51 platinum refractory 51 common hematologic malignancy 51 Ewing Sarcoma 51 glioblastoma cells 51 amyotrophic lateral sclerosis ALS 51 PC# cells 51 CD8 + 51 GRNOPC1 cells 51 cyclin E 51 refractory chronic lymphocytic